| pubmed-article:8646807 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:8646807 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:8646807 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8646807 | pubmed:dateCreated | 1996-7-25 | lld:pubmed |
| pubmed-article:8646807 | pubmed:abstractText | Ifosfamide (IFX) and mitoxantrone (MXN) have been found to be effective against advanced epithelial ovarian cancer. The combination of these two agents has not yet been tested in this setting but seems to be rational, given the different action mechanisms of these drugs and their not completely overlapping side effects. Between June 1987 and November 1991, 37 patients with advanced ovarian carcinoma recurrent or refractory to primary cisplatin-based chemotherapy entered the study. Therapy consisted of MXN, given i.v. at 10 mg/m2 on day 1 and IFX given i.v. at 2,000 mg/m2 per day on days 1-3 with mesna. The cycles were repeated every 3 weeks. Four patients achieved a complete remission and three achieved a partial remission, for response rates of 18.9% [95% confidence interval (CI) 6.3-31.5%] in the whole sample and 38.8% (95% CI 16.3-61.3%) in the subset of 18 patients responding to first-line cisplatin. No response was obtained in the remaining patients, whose disease was refractory to primary platinum-based chemotherapy. Clinically significant toxicity (WHO grades 3-4) included leukopenia in 46% of the patients and anemia in 32.5%. The non-hematologic toxicity was mild, except for reversible alopecia (57%) and nausea and vomiting (48.5%). This regimen seems attractive for patients who have either failed or not received platinum retreatment, especially when limiting neurotoxicity occurs. Further studies are warranted to establish the relative impact of both of these agents. | lld:pubmed |
| pubmed-article:8646807 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8646807 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8646807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8646807 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8646807 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:CalabresiFF | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:NardiMM | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:IacovelliAA | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:AtlanteGG | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:PolleraC FCF | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:MarollaPP | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:RuggeriE MEM | lld:pubmed |
| pubmed-article:8646807 | pubmed:author | pubmed-author:Della... | lld:pubmed |
| pubmed-article:8646807 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8646807 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:8646807 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8646807 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8646807 | pubmed:pagination | 298-301 | lld:pubmed |
| pubmed-article:8646807 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:meshHeading | pubmed-meshheading:8646807-... | lld:pubmed |
| pubmed-article:8646807 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8646807 | pubmed:articleTitle | A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. | lld:pubmed |
| pubmed-article:8646807 | pubmed:affiliation | Department of Medical Oncology I, Regina Elena Cancer Institute, Rome, Italy. | lld:pubmed |
| pubmed-article:8646807 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8646807 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8646807 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
